Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2016

Conditions
ThrombocytopeniaHepatitis C
Interventions
DRUG

Eltrombopag

Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.

Trial Locations (1)

75390-8887

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT01821625 - Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C | Biotech Hunter | Biotech Hunter